Irreversible Electroporation of the Pancreas Using Parallel Plate Electrodes in a Porcine Model: A Feasibility Study

Steffi J E Rombouts, Maarten W Nijkamp, Willemijn P M van Dijck, Lodewijk A A Brosens, Maurits Konings, R van Hillegersberg, Inne H M Borel Rinkes, Jeroen Hagendoorn, Fred H Wittkampf, I Quintus Molenaar, Steffi J E Rombouts, Maarten W Nijkamp, Willemijn P M van Dijck, Lodewijk A A Brosens, Maurits Konings, R van Hillegersberg, Inne H M Borel Rinkes, Jeroen Hagendoorn, Fred H Wittkampf, I Quintus Molenaar

Abstract

Background: Irreversible electroporation (IRE) with needle electrodes is being explored as treatment option in locally advanced pancreatic cancer. Several studies have shown promising results with IRE needles, positioned around the tumor to achieve tumor ablation. Disadvantages are the technical difficulties for needle placement, the time needed to achieve tumor ablation, the risk of needle track seeding and most important the possible occurrence of postoperative pancreatic fistula via the needle tracks. The aim of this experimental study was to evaluate the feasibility of a new IRE-technique using two parallel plate electrodes, in a porcine model.

Methods: Twelve healthy pigs underwent laparotomy. The pancreas was mobilized to enable positioning of the paddles. A standard monophasic external cardiac defibrillator was used to perform an ablation in 3 separate parts of the pancreas; either a single application of 50 or 100J or a serial application of 4x50J. After 6 hours, pancreatectomy was performed for histology and pigs were terminated.

Results: Histology showed necrosis of pancreatic parenchyma with neutrophil influx in 5/12, 11/12 and 12/12 of the ablated areas at 50, 100, and 4x50J respectively. The electric current density threshold to achieve necrosis was 4.3, 5.1 and 3.4 A/cm2 respectively. The ablation threshold was significantly lower for the serial compared to the single applications (p = 0.003). The content of the ablated areas differed between the applications: areas treated with a single application of 50 J often contained vital areas without obvious necrosis, whereas half of the sections treated with 100 J showed small islands of normal looking cells surrounded by necrosis, while all sections receiving 4x 50 J showed a homogeneous necrotic lesion.

Conclusion: Pancreatic tissue can be successfully ablated using two parallel paddles around the tissue. A serial application of 4x50J was most effective in creating a homogeneous necrotic lesion.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Paddles placement.
Fig 1. Paddles placement.
Placement of paddles prior to IRE procedure.
Fig 2. Macroscopic changes.
Fig 2. Macroscopic changes.
Macroscopic image directly after IRE in situ: the red dotted line indicates the location of the paddle at the ventral side, damaged pancreatic tissue (black arrow) and undamaged pancreatic tissue (green arrow).
Fig 3. Macroscopic changes.
Fig 3. Macroscopic changes.
Macroscopic image of a cross-section of the ablated area after formalin fixation: the red dotted line indicates the border of the macroscopic damaged area in the central part of this section.
Fig 4. Microscopic image.
Fig 4. Microscopic image.
Microscopic histology of porcine pancreatic tissue treated with a single application of 50 J; The location of both paddles is shown as two black bars with a length of 25 mm on both sides of the tissue. The parenchyma is marked as necrotic (red), transition area (orange); vital (green). Magnifications (H&E stain; scale bar 600 mircon.): vital pancreatic cells (left), vital cells in the upper right amid a completely necrotic area (middle) and a completely necrotic area characterized by nuclear dust.
Fig 5. Microscopic histology of porcine pancreatic…
Fig 5. Microscopic histology of porcine pancreatic tissue treated with a series of 4 applications of 50 J; The location of both paddles is shown as two black bars with a length of 25 mm on both sides of the tissue.
A homogeneous necrotic area marked red with a border zone (orange) on both sides is shown. Magnifications (H&E stain; scale bar 600 mircon.): border zone defined as a transition area consisting of vital and necrotic cells alternating (left and right) and a completely necrotic area which shows only nuclear dust.
Fig 6. Density curve.
Fig 6. Density curve.
Lower panel: A cross-section of the 2 circular paddles with a diameter of 25 mm and the plane in the middle between them (dashed line).Upper section: Current density curve in the middle plane between the 2 paddles for a tissue thickness of 7 millimeters and a nominal total ablation current of 1 Ampere.

References

    1. Moss RA, Lee C. Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther. 2010;3:111–27.
    1. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27(23):3778–85. 10.1200/JCO.2008.20.9007
    1. Rocha Lima C, Green M, Rotche R, Miller JW, Jeffrey G, Cisar L, et al. Irinotecan plus gemcitabine results in no survivaladvantage compared with gemcitabine monotherapy in patients withlocally advanced or metastatic pancreatic cancer despite increasedtumor response rate. J Clin Oncol. 2004;22:3776–83. 10.1200/JCO.2004.12.082
    1. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23(15):3509–16. 10.1200/JCO.2005.06.023
    1. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–13. 10.1200/jco.1997.15.6.2403
    1. Rombouts SJ, Walma MS, Vogel J a., van Rijssen LB, Wilmink JW, Mohammad NH, et al. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2016;4.
    1. Rombouts SJE, Vogel JA, Van Santvoort HC, Van Lienden KP, Van Hillegersberg R, Busch ORC, et al. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. British Journal of Surgery. 2015.
    1. Weaver JC, Vaughan TE, Chizmadzhev Y. Theory of skin electroporation: implications of straight-through aqueous pathway segments that connect adjacent corneocytes. J Investig Dermatol Symp Proc [Internet]. 1998;3(2):143–7.
    1. Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat. 2007;6(1):37–48.
    1. Davalos R V., Mir LM, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33(2):223–31.
    1. Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat [Internet]. 2007;6(4):307–12.
    1. Du Pré BC, Van Driel VJ, Van Wessel H, Loh P, Doevendans PA, Goldschmeding R, et al. Minimal coronary artery damage by myocardial electroporation ablation. Europace. 2013;15(1):144–9. 10.1093/europace/eus171
    1. Neven K, Driel V Van, Wessel H Van, Es R Van, Pr?? B Du, Doevendans PA, et al. Safety and feasibility of closed chest epicardial catheter ablation using electroporation. Circulation: Arrhythmia and Electrophysiology. 2014. p. 913–9.
    1. Girelli R, Frigerio I, Giardino A, Regi P, Gobbo S, Malleo G, et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbeck’s Arch Surg. 2013;398(1):63–9.
    1. Cantore M, Girelli R, Mambrini a, Frigerio I, Boz G, Salvia R, et al. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. Br J Surg [Internet]. 2012;99(8):1083–8. 10.1002/bjs.8789
    1. Martin RCG, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol. 2013;20 Suppl 3:S443–9.
    1. Wu Y, Tang Z, Fang H, Gao S, Chen J, Wang Y, et al. High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer 1. J Surg Oncol. 2006;94(5):392–5. 10.1002/jso.20580
    1. Thomson KR, Kavnoudias H, Neal RE. Introduction to Irreversible Electroporation-Principles and Techniques. Tech Vasc Interv Radiol. 2015;18(3):128–34. 10.1053/j.tvir.2015.06.002
    1. Institute for Laboratory Animal Research. Guide for the Care and Use of Laboratory Animals: 8th Ed. Guide for the Care and Use of Laboratory Animals; 2011. 118 p.
    1. Fritz S, Sommer CM, Vollherbst D, Wachter MF, Longerich T, Sachsenmeier M, et al. Irreversible Electroporation of the Pancreas Is Feasible and Safe in a Porcine Survival Model. Pancreas. 2015;44(5):791–8. 10.1097/MPA.0000000000000331
    1. Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the pancreas in swine: A pilot study. HPB. 2010;12(5):348–51. 10.1111/j.1477-2574.2010.00174.x
    1. Bower M, Sherwood L, Li Y, Martin R. Irreversible electroporation of the pancreas: Definitive local therapy without systemic effects. J Surg Oncol. 2011;104(1):22–8. 10.1002/jso.21899
    1. Wiersinga WJ, Jansen MC, Straatsburg IH, Davids PH, Klaase JM, Gouma DJ, et al. Lesion progression with time and the effect of vascular occlusion following radiofrequency ablation of the liver. Br J Surg. 2003;90(3):306–12. 10.1002/bjs.4040
    1. American Cancer Society [Internet]. 2016 [cited 2016 Jul 7]. p. 2016. Available from:
    1. Pancreatic Cancer UK [Internet]. Pancreatic CAncer UK. 2013 [cited 2016 Jul 7]. Available from:
    1. Martin RCG, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C, et al. Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation Safety and Efficacy. Ann Surg. 2015;262:486–94. 10.1097/SLA.0000000000001441
    1. Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol [Internet]. Elsevier Inc.; 2011;22(5):611–21. 10.1016/j.jvir.2010.12.014

Source: PubMed

3
Subscribe